Idorsia (IDIA) Stock Overview
A biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
IDIA Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Idorsia Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 3.71 |
| 52 Week High | CHF 4.85 |
| 52 Week Low | CHF 0.69 |
| Beta | 1.75 |
| 1 Month Change | -8.62% |
| 3 Month Change | 12.42% |
| 1 Year Change | 433.43% |
| 3 Year Change | -70.08% |
| 5 Year Change | -85.24% |
| Change since IPO | -72.82% |
Recent News & Updates
Recent updates
Idorsia Ltd (VTX:IDIA) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Dec 22
Little Excitement Around Idorsia Ltd's (VTX:IDIA) Revenues As Shares Take 29% Pounding
Nov 07Idorsia Ltd (VTX:IDIA) Stock Catapults 38% Though Its Price And Business Still Lag The Industry
Sep 14
Global Expansion And FDA Review Will Moderate Overvaluation
Key Takeaways Market optimism for rapid revenue growth may be premature, with unvalidated access, uncertain drug uptake, and regulatory outcomes adding risk to earnings expectations. Longer-term valuation appears inflated by pipeline commercialization hopes, while rising costs and increasing pricing scrutiny threaten future margins and profitability.New Forecasts: Here's What Analysts Think The Future Holds For Idorsia Ltd (VTX:IDIA)
Aug 24There's Reason For Concern Over Idorsia Ltd's (VTX:IDIA) Massive 46% Price Jump
Jul 19Improved Revenues Required Before Idorsia Ltd (VTX:IDIA) Stock's 71% Jump Looks Justified
Dec 19One Idorsia Ltd (VTX:IDIA) Analyst Has Been Cutting Their Forecasts
Nov 06Market Cool On Idorsia Ltd's (VTX:IDIA) Revenues Pushing Shares 33% Lower
Nov 04Take Care Before Jumping Onto Idorsia Ltd (VTX:IDIA) Even Though It's 25% Cheaper
Sep 18Idorsia Ltd (VTX:IDIA) Stock Rockets 26% But Many Are Still Ignoring The Company
May 30Idorsia Ltd (VTX:IDIA) Analysts Are Reducing Their Forecasts For This Year
May 26Idorsia Ltd (VTX:IDIA) Analysts Just Slashed Next Year's Revenue Estimates By 17%
May 01Industry Analysts Just Made A Captivating Upgrade To Their Idorsia Ltd (VTX:IDIA) Revenue Forecasts
Apr 05Need To Know: Analysts Are Much More Bullish On Idorsia Ltd (VTX:IDIA) Revenues
Mar 10Idorsia Ltd (VTX:IDIA) Stock Catapults 38% Though Its Price And Business Still Lag The Industry
Mar 08There's No Escaping Idorsia Ltd's (VTX:IDIA) Muted Revenues Despite A 37% Share Price Rise
Dec 28The Idorsia Ltd (VTX:IDIA) Analysts Have Been Trimming Their Sales Forecasts
Jul 27Idorsia Ltd's (VTX:IDIA) P/S Still Appears To Be Reasonable
Jun 14Shareholder Returns
| IDIA | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | 1.8% | 0.04% | 3.1% |
| 1Y | 433.4% | 17.6% | 6.7% |
Return vs Industry: IDIA exceeded the Swiss Biotechs industry which returned 20.6% over the past year.
Return vs Market: IDIA exceeded the Swiss Market which returned 6.4% over the past year.
Price Volatility
| IDIA volatility | |
|---|---|
| IDIA Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in CH Market | 9.0% |
| 10% least volatile stocks in CH Market | 1.9% |
Stable Share Price: IDIA's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: IDIA's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Srishti Gupta | www.idorsia.com |
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia.
Idorsia Ltd Fundamentals Summary
| IDIA fundamental statistics | |
|---|---|
| Market cap | CHF 933.09m |
| Earnings (TTM) | -CHF 117.94m |
| Revenue (TTM) | CHF 232.51m |
Is IDIA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IDIA income statement (TTM) | |
|---|---|
| Revenue | CHF 232.51m |
| Cost of Revenue | CHF 138.79m |
| Gross Profit | CHF 93.72m |
| Other Expenses | CHF 211.67m |
| Earnings | -CHF 117.94m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 26, 2026
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 40.31% |
| Net Profit Margin | -50.72% |
| Debt/Equity Ratio | -101.2% |
How did IDIA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/04 07:52 |
| End of Day Share Price | 2026/02/04 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Idorsia Ltd is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rosie Turner | Barclays |
| Alistair Campbell | Berenberg |
| Sachin Jain | BofA Global Research |